The benefits and challenges of PEGylating small molecules

Pharmaceutical Technology

Volumn 32, Issue 7, 2008, Pages 88-94

  Riley, Timothy ^a   Riggs Sauthier, Jennifer ^a  

^a NEKTAR THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; ETHYLENE GLYCOL; GLYCOLS; POLYETHYLENE GLYCOLS; SUPRAMOLECULAR CHEMISTRY;

HALF LIFE; PEGYLATED DRUG; PEGYLATION; POLYETHYLENE GLYCOL (PEG); SMALL MOLECULES;

MOLECULES;

ADENOSINE DEAMINASE; ASPARAGINASE MACROGOL; MACROGOL; MORPHINE; PEGADEMASE; PEGAPTANIB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; MACROMOLECULE; REVIEW;

EID: 48249092240     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (1)

1. A. Abuchowski et al., "Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine Liver Catalase," J. Biol. Chem. 252 (11), 3582-3586 (1977).